<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32116059</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1744-7607</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Expert opinion on drug metabolism &amp; toxicology</Title>
          <ISOAbbreviation>Expert Opin Drug Metab Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evaluation of zonisamide for the treatment of focal epilepsy: a review of pharmacokinetics, clinical efficacy and adverse effects.</ArticleTitle>
        <Pagination>
          <StartPage>169</StartPage>
          <EndPage>177</EndPage>
          <MedlinePgn>169-177</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/17425255.2020.1736035</ELocationID>
        <Abstract>
          <AbstractText><b>Introduction</b>: Zonisamide is a benzisoxazole with 3-methanesulfonamide side chain, chemically unrelated with other anticonvulsants, and approved as mono-therapy of newly diagnosed focal epilepsy with or without secondary generalization in adults or adjunctive therapy in the treatment of partial seizures, with or without secondary generalization, in adults, adolescents, and children aged 6 years and above.<b>Areas covered</b>: Pharmacokinetics, clinical efficacy, and the adverse effects of zonisamide are discussed in the article. The discussion is based on data from published preclinical studies, clinical trials, observational studies, systematic reviews, and approved summary of product characteristics.<b>Expert opinion</b>: Zonisamide is an anticonvulsant with multiple mechanisms of action on neuronal tissue, which achieves seizure freedom in more than 80% of patients with newly-onset focal epilepsy and in 6.2 to 18.1% of patients with focal onset seizures inadequately controlled by first-line anticonvulsants. Within the recommended dose range, it follows linear kinetic of elimination; it is metabolized in the liver by two cytochrome isoforms, so pharmacokinetic interactions are rare and with little clinical significance. Up to 10% of patients taking zonisamide will have problems with weight loss and more than 10% with irritability, confusion or depression, and long-lasting therapy may cause renal calculi in 1.2% of patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Janković</LastName>
            <ForeName>Slobodan M</ForeName>
            <Initials>SM</Initials>
            <Identifier Source="ORCID">0000-0002-1519-8828</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>03</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Expert Opin Drug Metab Toxicol</MedlineTA>
        <NlmUniqueID>101228422</NlmUniqueID>
        <ISSNLinking>1742-5255</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004828" MajorTopicYN="N">Epilepsies, Partial</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Zonisamide</Keyword>
        <Keyword MajorTopicYN="N">clinical efficacy</Keyword>
        <Keyword MajorTopicYN="N">focal onset seizures</Keyword>
        <Keyword MajorTopicYN="N">pharmacokinetics</Keyword>
        <Keyword MajorTopicYN="N">side effects</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32116059</ArticleId>
        <ArticleId IdType="doi">10.1080/17425255.2020.1736035</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
